Gather with other pharmacy professionals and visit the exhibit hall at the ASHP Summer Meetings & Exhibition, and learn how these companies and their products
BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta® in
Product & Service Providers in: CLEANROOMS, ISOLATORS, HOODS, AND GLOVEBOXES GPO SUPPLIES PHARMACEUTICAL MANUFACTURERS As Seen In: View Amneal Pharmaceuticals’ Ad:
Available when you need them most Multi-source Injectable Products from Amneal Our ever-expanding portfolio includes corticosteroids and complex injectables that you can count on. At
Available when you need them most Multi-source Injectable Products from Amneal Our ever-expanding portfolio includes corticosteroids and complex injectables that you can count on. At
Peruse the groundbreaking Exhibit Hall, and learn for yourself how these innovative companies and their products are helping to define what is important to your
Key injectable new product launch brings year-to-date injectables launches to 6 November 2, 2022 BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the
First of three approved U.S. oncology biosimilars Amneal expects to launch October 03, 2022 BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the
The NACDS Total Store Expo is the largest gathering of retailers and suppliers in the health and wellness industry. Discover new and innovative products, technology
Brings year-to-date generics launches to 16; on-track for 20-30 this year BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced
